ARCHIVES

FDA Approves Gemzar For Ovarian Cancer, Contradicting ODAC Recommendation; Continues Agency Trend to Recognize Progression-Free Survival As An Endpoint.

This article is from The Cancer Letter archive.

Vol. 32 No. 28 | July 21, 2006

Download PDF Visit The Full Archive

Related Articles

NCI Buys Building For PDQ, ICRDB With Donated Money

December 10, 1982

Ovarian Cancer Symptom Indices May Need to be Re-Evaluated

January 27, 2012

Cancer Education: NCI Offers Training In Epidemiology And Genetics

April 17, 1998

“I’m Not Bummed Out By This” – Broder

December 22, 1994

In Brief: No Such Thing As Premature Data, Fisher Says- Only Immature Evaluation, Premature Application

June 20, 1980

Taking on question of cost and outcomes, CMS turns to expert in cancer care quality.

June 3, 2005